In both tumor models, domatinostat increased the number of intratumoral cytotoxic CD8+ T cells (cytotoxic T lymphocytes, CTLs), with the relative effect being more pronounced in tumors with low levels of pre-existing CTLs. The gene discussed is CD8A; the disease is neoplasm.